Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Bile acid recycling inhibitors for treatment of obesity and diabetes

a obesity technology, applied in the field of bile acid recycling inhibitors for treatment of obesity and diabetes, can solve the problems of obesity, arthritis, pain and stiffness, overeating and obesity have become a problem in the general population, and achieve the effects of reducing or inhibiting the recycling of bile acid salts, enhancing l-cell secretion of enteroendocrine peptides, and increasing l-cell secretion of enteroendocrin

Inactive Publication Date: 2012-06-21
SATIOGEN PHARMA
View PDF3 Cites 45 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The patent text describes methods for treating obesity and diabetes using compounds that inhibit the recycling of bile acids in the gastrointestinal tract. These compounds, known as ASBTIs, can reduce food intake, induce satiety, reduce blood glucose levels, and enhance the secretion of enteroendocrine peptides. The methods may also involve the use of other therapeutic agents such as DPP-IV inhibitors, biguanides, incretin mimics, thiazolidinediones, GLP-1 or analogues thereof, and TGR5 agonists. The combination of an ASBTI and another therapeutic agent may provide enhanced effects in treating obesity and diabetes."

Problems solved by technology

In addition, increased body weight due to obesity places a burden on joints causing arthritis, pain, and stiffness.
Overeating and obesity have become a problem in the general population.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bile acid recycling inhibitors for treatment of obesity and diabetes
  • Bile acid recycling inhibitors for treatment of obesity and diabetes
  • Bile acid recycling inhibitors for treatment of obesity and diabetes

Examples

Experimental program
Comparison scheme
Effect test

example 1

Synthesis of 1-phenethyl-1-((1,4-diazabicyclo[2.2.2]octanyl)pentyl)imidodicarbonimidic diamide, Iodide Salt

[0452]

Step 1: Synthesis of 5-(1,4-diazabicyclo[2.2.2]octanyl)-1-iodo pentane, Iodide Salt

[0453]

[0454]1,4-diazabicyclo[2.2.2]octane is suspended in THF. Diiodopentane is added dropwise and the mixture is refluxed overnight. The reaction mixture is filtered.

Step 2: Synthesis of N-phenethyl-5-(1,4-diazabicyclo[2.2.2]octanyl)-1-iodo pentane, Iodide Salt

[0455]

[0456]5-(1,4-diazabicyclo[2.2.2]octanyl)-1-iodo pentane, iodide salt is suspended in acetonitrile. Phenethylamine is added dropwise and the mixture is refluxed overnight. The reaction mixture is filtered.

Step 3: Synthesis of 1-phenethyl-1-((1,4-diazabicyclo[2.2.2]octanyl)pentyl)imidodicarbonimidic diamide, Iodide Salt

[0457]N-phenethyl-5-(1,4-diazabicyclo[2.2.2]octanyl)-1-iodo pentane, iodide salt is heated with dicyanodiamide in n-butanol for 4 h. The reaction mixture is concentrated under reduced pressure.

[0458]The compounds i...

example 2

In Vitro Assay for Inhibition of ASBT-Mediated Bile Acid Uptake

[0459]Baby hamster kidney (BHK) cells are transfected with cDNA of human ASBT. The cells are seeded in 96-well tissue culture plates at 60,000 cells / well. Assays are run within 24 hours of seeding.

[0460]On the day of the assay the cell monolayer is washed with 100 mL of assay buffer. The test compound is added to each well along with 6 mM [14C] taurocholate in assay buffer (final concentration of 3 mM [14C] taurocholate in each well). The cell cultures are incubated for 2 h at 37° C. The wells are washed with PBS. Scintillation counting fluid is added to each well, the cells are shaken for 30 minutes prior to measuring amount of radioactivity in each well. A test compound that has significant ASBT inhibitory activity provides an assay wherein low levels of radioactivity are observed in the cells.

example 3

In Vitro Assay for Secretion of GLP-1

[0461]Human NCI-H716 cells are used as a model for L-cells. Two days before each assay experiment, cells are seeded in 12-well culture plates coated with Matrigel® to induce cell adhesion. On the day of the assay, cells are washed with buffer. The cells are incubated for 2 hours with medium alone, or with test compound. The extracellular medium is assayed for the presence of GLP-1. Peptides in the medium are collected by reverse phase adsorption and the extracts are stored until assay. The presence of GLP-1 is assayed using an antiserum directed against the carboxyl terminus of GLP-1 amide (total immunoreactive GLP-1; Affinity Research Products, Nottingham, UK). The detection of increased levels of GLP-1 in a well containing a test compound identifies the test compound as a compound that can enhance GLP-1 secretions from L-cells.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
time periodsaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes.

Description

CROSS-REFERENCE[0001]This application claims the benefit of U.S. Provisional Application No. 61 / 118,356 filed Nov. 26, 2008; U.S. Provisional Application No. 61 / 239,657 filed Sep. 3, 2009; U.S. Provisional Application No. 61 / 239,636 filed Sep. 3, 2009; U.S. Provisional Application No. 61 / 239,663 filed Sep. 3, 2009; and U.S. Provisional Application No. 61 / 255,205 filed Oct. 27, 2009; each of which is incorporated herein by reference in its entirety.BACKGROUND OF THE INVENTION[0002]Obesity is a medical condition affecting numerous humans in a number of countries throughout the world, and is associated with or induces other diseases or conditions. In particular, obesity is a serious risk factor for diseases and conditions such as diabetes, hypertension, gallbladder disease, cancer, polycystic ovary disease and arteriosclerosis and can contribute to elevated levels of cholesterol in the blood. In addition, increased body weight due to obesity places a burden on joints causing arthritis,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/4995A61K31/454A61K31/40A61K31/7042A61K31/155A61K31/5377A61K31/554A61P1/00A61K31/4453A61K31/495
CPCA61K31/155A61K31/16A61K31/40A61K31/554A61K31/454A61K31/495A61K31/5377A61K31/452A61K31/38A61P1/00A61P1/04A61P15/00A61P15/08A61P29/00A61P3/00A61P3/04A61P3/08A61P43/00A61P7/00A61P9/00A61P9/04A61P9/10A61P3/10A61K31/4985A61K31/4995A61K31/55C07C279/26C07D207/08A61K9/0053A61K9/4808A61K9/4825A61K9/485A61K9/4858A61K9/4866
Inventor YOUNG, ANDREW A.GEDULIN, BRONISLAVAGREENE, HOWARD E.
Owner SATIOGEN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com